Clinical Value of Ultrasound-guided Polidocanol Chemical Ablation Combined with Mifepristone in the Treatment of Uterine Fibroids
Objective:To investigate the clinical value of ultrasound-guided Polidocanol chemical ablation combined with Mifepristone in the treatment of uterine fibroids.Method:A total of 80 patients with uterine fibroids who admitted to Sheyang County People's Hospital from April 2022 to April 2023 were selected as the study objects and divided into the control group and the observation group by random number table method,with 40 cases in each group.The control group was treated with Mifepristone,and the observation group was treated with ultrasound-guided Polidocanol chemical ablation combined with Mifepristone.The clinical efficacy,fibroids volume,fibroids diameter and ovarian function[estradiol(E2),follicle-stimulating hormone(FSH),luteinizing hormone(LH)]before and after treatment were compared between two groups.Result:The total effective rate of the observation group was higher than that of the control group,and the difference was statistically significant(P<0.05).Before treatment,there were no significant differences in the fibroids volume,fibroids diameter and ovarian function between two groups(P>0.05);after treatment,the fibroids volume in the observation group was smaller than that in the control group,the fibroids diameter was shorter than that in the control group,and the levels of E2,FSH and LH were lower than those in the control group,the differences were statistically significant(P<0.05).Conclusion:Compared with Mifepristone alone,ultrasound-guided Polidocanol chemical ablation combined with Mifepristone in the treatment of uterine fibroids is more effective in improving the treatment efficiency,reducing the fibroids volume,shortening the fibroids diameter and improving ovarian function.
Ultrasound-guided Polidocanol chemical ablationMifepristoneUterine fibroidsClinical efficacyOvarian function